

Application No. (if known): 10/687,712

Attorney Docket No.: 03940/100K485-US4

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No 983945615-03

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

March 12, 2004
on February 25, 2004

Date

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pgs); and (2) Her erences Information Disclosure Statement/SB/08 (refs. cited not attached)

O DExamples Mail Label No.	Dated:	
. 5		

Docket No.: 03940/100K485-US4

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Daniela Gutman et al.

Application No.: 10/687,712 Confirmation No.: Not Yet Assigned

Filed: October 16, 2003 Art Unit: Not Yet Assigned

For: METHOD AND REAGENTS FOR N- Examiner: Not Yet Assigned

ALKYLATING UREIDES

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. This PTO/SB/08 (list of references) replaces that filed on October 16, 2003. The PTO/SB/08 filed with the Information Disclosure Statement on October 16, 2003 does not indicate the country code for each listed foreign patent document. This error has been corrected in the PTO/SB/08 filed herewith. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Copies of all of the documents listed on the PTO/SB/08, except for U.S. Patent Nos. 6,093,820 and 6,664,262, were cited by or submitted to the Patent Office during prosecution of the parent application (U.S. Serial No. 10/073,051) to the present application. Copies of U.S. Patent Nos. 6,093,820 and 6,6634,262 are submitted herewith.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)), therefore, no fee is due. If fees are due in connection with the filing, the Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: February 25, 2004

Respectfully submitted

Jay P. Lessler

Registration No.: 41,151 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

			o persons are required to re	espond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Suc	Substitute for form 1449A/PTO			Application Number	10/687,712	
11	VEORMATION	N DIS	CLOSURE	Filing Date	October 16, 2003	
l s	STATEMENT BY APPLICANT			First Named Inventor	Daniela Gutman	
				Art Unit	Not Yet Assigned	
(use as many sheets as necessary)			ecessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	03940/100K485-US4	

U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Number Publication Date Name of Patentee or Applicant	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevant
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	of Cited Document	Passages or Relevant Figures Appear
	1	10/375,340	_	Gutman et al.	
	2	4,628,056	12/1986	Levitt et al.	
	3	6,093,820	07/25/2000	Gutman et al.	
	4	6,664,262	12/16/2003	Gutman et al.	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]		
	5	WO-02/07729	01/31/02			\Box		
	6	DE-2622981	12/1977			\Box		
	7	DE-4028040	3/1992			\Box		
	8	EP-726252	01/31/96			\Box		
	9	DE-1939787	02/19/70			$\dagger \Box$		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), till item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number publisher, city and/or country where published.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	Thacker et al., "A Method for Determination of 5,5 Diphenylbarbituric Acid and Separation from 1,3 Dimethoxymethyl 5,5 Diphenylbarbituric Acid in Plasma by High Performance Liquid Chromatography," Journal of Chromatography B, 710:149 155 (1998).	
	11	Raines, et al., "Conversion of Dimethoxymethyl Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Dog," The FASEB J., 13(4):A475, Ansract 394.2 (1999).	
	12	Raines, et al., "Conversion of Dimethoxymethyl Diphenylbarbituric Acid (DMMDPB) to Diphenylbarbituric Acid (DPB) in the Rat," The FASEB J., 10:A 155, Abstract 895 (1996).	
	13	Raines, et al., "Serum and Brain Levels of 5 5 Diphenylbarbituric Acid (DPB) After Administration of dimethoxymethyl Diphenylbarbituric Acid (DMMDPB) in the Rat," Epilepsia, 37:Supp. 5, p. 23, Abstract 1.84 (1996).	
	14	Raines, et al., "Differential Selectivity of Several Barbiturates on Experimental Seizures and Neurotoxicity in the Mouse," Epilepsia, 20:105 113 (1979).	
	15	Raines, et al., "The Effects of 5,5 Diphenylbarbituric Acid on Experimental Seizures in Rats: Correlation Between Plasma and Brain Concentrations and Anticonvulsant Activity," Epilepsia, 16:575 581 (1975).	
	16	Raines, et al., "A Comparison of the Anticonvulsant, Neurotoxic and Lethal Effects of Diphenylbarbituric Acid Phenobarbital and Diphenylhydantoin in the Mouse," Journal of Pharmacology and Experimental Therapeutics, 186:315	
	17	The Merck Index, 10th Ed., 1983, p. 544 (entry 3697).	

		
Examiner I.	Date	
	Date	l .
Signature	Considered	j
Signature	Considered	
		

PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ler the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/687,712 INFORMATION DISCLOSURE Filing Date October 16, 2003 STATEMENT BY APPLICANT First Named Inventor Daniela Gutman Art Unit Not Yet Assigned (use as many sheets as necessary) Examiner Name Not Yet Assigned 2 2 03940/100K485-US4 of Sheet Attorney Docket Number

18	Susumu Kamata, Nobuhiro Haga, Takeaki Matsui and Wataru Nagata, "Studies of Antitumor-Active 5-Fluorouracil Derivatives. I. Synthesis of N-Phthalidyl 5-Fluorouracil Derivatives", Chemical And Pharmaceutical Bulletin, Vol. 33, No. 8, 1985, pp. 3160-3175.	
19	J.P. Gesson, JC Jacquesy, D. Rambaud, "A practical method for N-alkylation of succinimide and glutarimide", Bulletin De La Societe Chimique De France, Vol. 129, No. 3, 1992, pp. 227-231.	
20	P. Casara et al., "Synthesis of acid stable fluorinated acylnucleosides", Vol. 32, No. 31, 1991, pp. 3823-3826.	
21	Foye, "Principles of Medicinal Chemistry", 3rd ed., 1990, pp. 164, 179.	
22	Karger et al., "Methoxymethyl Methanesulfonate, A Novel Active Oxyalkylating Agent", Journal of the American Chemical Society, 91:5663 (1969).	
23	Aldrich Chemical Catalog, 1990-1991, p. 303.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	- T
Signature	Considere	ed

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.